SDGR Schrodinger, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1490978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.8%
TTM net income YoY66.3%
TTM EPS YoY67.1%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR—
Margins
Gross margin58.5%
Operating margin-49.6%
Net margin-22.0%
FCF margin-43.4%
EBITDA margin-47.5%
Returns
ROE-19.0%
ROA-9.4%
ROIC (approx.)-108.6%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets50.7%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.90x
Accruals ratio8.4%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $255.87M | $207.54M | $216.67M | $180.96M | $137.93M |
| Cost of revenue | $113.25M | $75.46M | $75.97M | $79.93M | $72.31M |
| Gross profit | $142.61M | $132.08M | $140.69M | $101.02M | $65.62M |
| R&D expense | $173.14M | $201.78M | $181.77M | $126.37M | $90.90M |
| SG&A expense | $95.41M | $99.68M | $99.15M | $90.83M | $64.01M |
| Operating income | -$166.90M | -$209.30M | -$177.45M | -$146.82M | -$111.44M |
| Pretax income | -$102.33M | -$185.71M | $42.92M | -$149.12M | -$100.81M |
| Income tax | $939,000 | $1.41M | $2.20M | $63,000 | $411,000 |
| Net income | -$103.27M | -$187.12M | $40.72M | -$149.19M | -$100.39M |
| EBITDA | -$160.87M | -$203.14M | -$171.90M | -$142.47M | -$108.60M |
| EPS (basic) | -1.41 | -2.57 | 0.57 | -2.10 | -1.42 |
| EPS (diluted) | -1.41 | -2.57 | 0.54 | -2.10 | -1.42 |
| Weighted avg. shares (diluted) | 73.44M | 72.67M | 74.99M | 71.17M | 70.59M |
| Balance sheet | |||||
| Cash & equivalents | $230.52M | $162.66M | $161.07M | $95.72M | $123.27M |
| Short-term investments | $164.95M | $204.80M | $307.69M | $360.61M | $456.21M |
| Receivables | $83.04M | $235.69M | $65.99M | $55.95M | $31.74M |
| Current assets | $519.26M | $634.99M | $567.80M | $533.99M | $625.06M |
| PP&E, net | $19.46M | $24.20M | $23.32M | $14.24M | $10.03M |
| Goodwill | $4.79M | $4.79M | $4.79M | $4.79M | $0 |
| Intangibles | — | — | $0 | $587,000 | $0 |
| Total assets | $726.16M | $823.23M | $802.96M | $688.59M | $756.49M |
| Current liabilities | $189.14M | $191.75M | $133.67M | $108.80M | $91.21M |
| Total liabilities | $362.11M | $401.78M | $254.40M | $240.68M | $199.40M |
| Shareholders' equity | $364.05M | $421.44M | $548.56M | $447.89M | $557.07M |
| Shares outstanding | — | — | 62.98M | 62.16M | 61.83M |
| Cash flow statement | |||||
| Operating cash flow | $13.90M | -$157.37M | -$136.73M | -$119.68M | -$70.67M |
| Capital expenditure | $1.44M | $7.31M | $13.40M | $8.01M | $7.17M |
| Free cash flow | $12.46M | -$164.68M | -$150.14M | -$127.70M | -$77.84M |
| Investing cash flow | $57.90M | $148.84M | $193.03M | $90.02M | -$16.81M |
| Financing cash flow | $2.93M | $10.12M | $9.05M | $2.11M | $7.95M |
| Depreciation & amortization | $6.02M | $6.16M | $5.55M | $4.34M | $2.85M |
| Stock-based compensation | $43.00M | $49.90M | $47.84M | $39.63M | $26.49M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.